Ents, vascular calcification, and bone disorder. Also, comparison with sevelamer carbonate, safety in bone and liver, well being financial effectiveness, dialysis technique and prescription really should also be concerned in the future research with LC.Abbreviations CKD-MBD: Chronic kidney disease mineral and bone disorder; ESRD: End-stage renal illness; LC: Lanthanum carbonate; RCT: Randomized controlled trials; iPTH: Intact parathyroid hormone; CC: Calcium carbonate; SH: Sevelamer hydrochlorid; CV: Cardiovascular; HD: Hemodialysis; CAPD: Continuous ambulatory peritoneal dialysis; CENTRAL: Cochrane Central Register of Controlled Trials; CBBs: Calcium-based binders; NCBs: Non-calcium binders; CT: Computed tomography; TAP: Total alkaline phosphatase; BAP: Bone-specific alkaline phosphatase); RR: Danger ratios; CI: Self-confidence intervals; MD: Mean difference; SMD: Standardised imply distinction; ROD: Renal osteodystrophy; DCOR: Dialysis Clinical Outcomes Revisited.Zhang et al. BMC Nephrology 2013, 14:226 http://biomedcentral/1471-2369/14/Page 13 ofCompeting interests The authors declared that they’ve no competing interests. Authors’ contributions ZCL was involved in conducting the literature searches, obtained and analysed research and wrote the manuscript in the paper. WJ was involved in conducting the literature searches, obtained and analysed research. LZ was involved inside the style on the study, adjudication on disagreements in data analysis, writing and editing of draft and final versions with the paper. FJM was involved within the design and style from the study. All authors have read and authorized the final manuscript. Acknowledgements The authors would prefer to acknowledge Professor Guanjian Liu in EvidenceBased Medicine Center of China, for his assistance within the conduct of this systematic assessment. The authors would also like to acknowledge Professor Takashi Shigematsu and Professor Maki Morikawa who present the detailed data to this systematic overview. Author details 1 Department of nephrology, West China Hospital of Sichuan University, Chengdu, China. 2Luzhou Medical College, Luzhou, China. Received: 23 April 2013 Accepted: 11 October 2013 Published: 17 October 2013 References 1. Moe S, Dr ke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G, Kidney Illness: Enhancing Worldwide Outcomes (KDIGO): Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Enhancing Global Outcomes (KDIGO). Kidney Int 2006, 69:1945?953. 2. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL: Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in individuals with chronic kidney disease: final results from the study to evaluate early kidney disease. Kidney Int 2007, 71(1):31?eight.2454490-66-3 web three.(R)-SITCP web Block GA, Pork FK: Re-evaluation of risks related with hyperphosphatemia and hyperparathyroidism in dialysis sufferers: Recommendations for a transform in management.PMID:33435721 Am J Kidney Dis 2000, 35:1226?237. 4. Palmer SC, Hayen A, Macaskill P, Pellegrini F, Craig JC, Elder GJ, Strippoli GF: Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular illness in individuals with chronic kidney illness: a systematic overview and meta-analysis. JAMA 2011, 305(11):1119?127. 5. Wald R, Sarnak MJ, Tighiouart H, Cheung AK, Levey AS, Eknoyan G, Miskulin DC: Disordered mineral metabolism in hemodialysis patients: an evaluation of cumulative effects in the Hemodialysis (HEMO) Study.